<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00291837</url>
  </required_header>
  <id_info>
    <org_study_id>CAM203</org_study_id>
    <nct_id>NCT00291837</nct_id>
  </id_info>
  <brief_title>CT-2106 for the Second Line Treatment of Ovarian Cancer</brief_title>
  <official_title>Phase II Open Label Study of CT-2106 as a Single Agent in Patients With Advanced Metastatic Ovarian Cancer Who Have Failed One Prior Platinum and Taxane Based Regimen</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CTI BioPharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CTI BioPharma</source>
  <brief_summary>
    <textblock>
      The purpose of this sudy is to determine the response rate of CT-2106 in patients with&#xD;
      advanced ovarian cancer who have failed one prior platinum and taxane based regimen.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2004</start_date>
  <completion_date type="Actual">December 2007</completion_date>
  <primary_completion_date type="Actual">June 2006</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>response rate</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>toxicity</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>response duration</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>time to progression</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>survival</measure>
  </secondary_outcome>
  <enrollment>40</enrollment>
  <condition>Ovarian Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CT-2106</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with advanced ovarian carcinoma, who have failed one prior platinum and&#xD;
             taxane containing regimen&#xD;
&#xD;
          -  Only one prior chemotherapy containing either cisplatin or carboplatin plus taxanes&#xD;
             administered concomitantly&#xD;
&#xD;
          -  At least one measurable lesion according to RECIST&#xD;
&#xD;
          -  ECOG performance status 0 or 1&#xD;
&#xD;
          -  at least 18 years old&#xD;
&#xD;
          -  Adequate haematological function&#xD;
&#xD;
          -  Adequate renal and hepatic functions&#xD;
&#xD;
          -  Normal coagulation parameters&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Platinum-sensitive patients (Group 2) who responded (CR or PR) to a 1st line therapy&#xD;
             and subsequently progressed or relapsed after a treatment-free interval of &gt; 12 months&#xD;
&#xD;
          -  Pregnant or lactating patients&#xD;
&#xD;
          -  Prior treatment with camptothecins&#xD;
&#xD;
          -  Presence or history of CNS metastasis or carcinomatous leptomeningitis;&#xD;
&#xD;
          -  Current active infection per investigator assessment;&#xD;
&#xD;
          -  Unresolved bowel obstruction or subobstruction, uncontrolled Crohn's disease or&#xD;
             ulcerative colitis;&#xD;
&#xD;
          -  Current history of chronic diarrhea &gt;= grade 1 (CTCAE version 3);&#xD;
&#xD;
          -  Surgery or radiotherapy ≤ 4 weeks before first study treatment. In case of&#xD;
             cytoreductive surgery for the progression of the disease, ≤ 2 weeks before the 1st&#xD;
             study treatment are allowed;&#xD;
&#xD;
          -  Other uncontrolled, serious illness or medical condition, as determined by the&#xD;
             investigator;&#xD;
&#xD;
          -  Concomitant (or within 4 weeks before inclusion) administration of any other&#xD;
             experimental drug under investigation;&#xD;
&#xD;
          -  Concurrent treatment with any other anti-cancer therapy;&#xD;
&#xD;
          -  Known HIV positivity or AIDS-related illness;&#xD;
&#xD;
          -  Patients who cannot be regularly followed up for psychological, social, familial or&#xD;
             geographic reasons.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hilary Calvert, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Newcastle General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Saint Brieuc</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Campobasso</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Birmingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Newcastle upon Tyne</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Surrey</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Italy</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>February 2010</verification_date>
  <study_first_submitted>February 14, 2006</study_first_submitted>
  <study_first_submitted_qc>February 14, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 15, 2006</study_first_posted>
  <last_update_submitted>February 24, 2010</last_update_submitted>
  <last_update_submitted_qc>February 24, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 26, 2010</last_update_posted>
  <keyword>ovarian</keyword>
  <keyword>CT-2106</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Ovarian Epithelial</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

